Presented as a late-breaking oral presentation at the European Respiratory Society (ERS) meeting in France, the PORtopulmonary hypertension Treatment wIth maCitentan ─ a randOmized clinical trial (PORTICO) showed
Alopecia areata is an autoimmune disease evidenced by hair loss and often linked with profound psychological consequences. The PF-06651600 is an oral JAK 3 inhibitor, while PF-06700841 is a
Actemra can be given alone or in combination with methotrexate (MTX) in patients with SJIA. In 2011, FDA approved the intravenous (IV) formulation of Actemra for patients two
ViraTherapeutics is engaged in the development of virus-based immunotherapeutics for the treatment of cancer. The current deal is based on an option and share purchase agreement signed by
In its advice, the SMC states that dupilumab can be used within the National Health Service (NHS) Scotland for the treatment of adults with moderate to severe atopic
Participants in the round, which was led by RiverVest Venture Partners, included new investors Qatar Investment Authority (QIA) and Redmile Group, and existing investors Alexandria Venture Investments, ARCH
The Finch 2 is a global, 24-week randomized, double-blind, placebo-controlled and phase 3 study of filgotinib in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response/intolerance to
The FDA has approved new dosage strength (16mg / 4mg) of Cassipa (buprenorphine and naloxone) sublingual film. It is also approved in both brand name and generic versions,
The study results confirmed its primary aim to show bioequivalence of an optimized formulation of HyNap-Dasa compared to Sprycel. The data will be instrumental in the design of
Since the initiative was announced in January 2018, more than 120 health organizations representing about a third of the nation’s hospitals have contacted Civica Rx and expressed a
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.